17269-81-7Relevant academic research and scientific papers
Synthesis of 2-bromomethyl-2,3-dihydrobenzofurans from 2-allylphenols enabled by organocatalytic activation of: N -bromosuccinimide
Furst, Carolina G.,Cota, Paulo H. P.,Dos Santos Wanderley, Taciano A.,Alberto, Eduardo E.
, p. 15677 - 15684 (2020)
2-Bromomethyl-2,3-dihydrobenzofurans are valuable and highly functionalized compounds that can be obtained by an intramolecular reaction between 2-allylphenols and a bromenium ion source (Br+). Due to the ineffectiveness of the safe and easy-to-handle brominating agent N-bromosuccinimide (NBS) to deliver the desired products, a catalytic process using a mixture of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and acetic acid was conceived. We hypothesized that this catalytic system delivers in situ acetyl hypobromite (AcOBr) as the active brominating agent, enabling the conversion of a range of 2-allylphenols with diverse electron densities to the products. The protocol was robust enough to permit the reaction to be scaled up to 10 mmols of starting material. Besides, the functional group interconversion with a 2-bromomethyl-2,3-dihydrobenzofuran derivative was successfully demonstrated. This journal is
THERAPEUTIC COMPOUNDS AND METHODS OF USE
-
Paragraph 0783; 0786; 0787, (2021/05/21)
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
Green Organocatalytic Synthesis of Dihydrobenzofurans by Oxidation-Cyclization of Allylphenols
Triandafillidi, Ierasia,Sideri, Ioanna K.,Tzaras, Dimitrios Ioannis,Spiliopoulou, Nikoleta,Kokotos, Christoforos G.
supporting information, p. 4254 - 4260 (2017/09/12)
A green and cheap protocol for the synthesis of dihydrobenzofurans via an organocatalytic oxidation of o -allylphenols is presented. The use of 2,2,2-trifluoroacetophenone and H 2 O 2 as the oxidation system, leads to a highly useful synthetic method, where a variety of substituted o -allylphenols were cyclized in high yields..
Synthesis and biological evaluation of novel n-[(7-pyridin-4-yl-2, 3-dihydro-benzofuran-2-yl) methyl]-(4-methyl-1, 2, 3-thiadiazole-5-yl) formamide as a potent immunosuppressant agent
Fan, Chen,Wang, Yubin,Lu, Peng,Xue, Xiaojian,She, Jinxiong
, p. 375 - 379 (2014/03/21)
N-[(7-pyridin-4-yl-2, 3-dihydro-benzofuran-2-yl) methyl]-(4-methyl-1, 2, 3-thiadiazole-5-yl)-Formamide (1) was synthesized and its immunosuppressive activity was evaluated. The results showed it had highly immunosuppressive activity and can be studied as lead compound in the development of immunosuppressant agent.
Silver-mediated trifluoromethylation-iodination of arynes
Zeng, Yuwen,Zhang, Laijun,Zhao, Yanchuan,Ni, Chuanfa,Zhao, Jingwei,Hu, Jinbo
supporting information, p. 2955 - 2958 (2013/04/10)
An unprecedented silver-mediated vicinal trifluoromethylation-iodination of arynes that quickly introduces CF3 and I groups onto aromatic rings in a single step to give o-trifluoromethyl iodoarenes has been developed. A new reactivity of AgCF3 has been revealed, and 2,2,6,6-tetramethylpiperidine plays an important role in this difunctionalization reaction.
MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME
-
Page/Page column 42-43, (2008/12/07)
The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs
Shrestha, Suja,Bhattarai, Bharat Raj,Lee, Keun-Hyeung,Cho, Hyeongjin
, p. 6535 - 6548 (2008/04/12)
A series of compounds containing one or two salicylic acid moieties were synthesized, and their efficacy to inhibit the phosphohydrolase activity of PTP1B examined. Some of the methylenedisalicylic acid derivatives were potent inhibitors of PTP1B. Of those derivatives, 3c exhibited about a 14-fold selectivity against TC-PTP, and this compound was tested in a mouse model for its efficacy to prevent diet-induced obesity. It effectively suppressed the increases in body weight and adipose mass, without any noticeable toxic effect. The compound also prevented increases in the plasma triglyceride, cholesterol, and nonesterified fatty acid concentrations; thus, expanding its therapeutic potential to other related metabolic diseases, such as hyperlipidemia and hypercholesterolemia.
Azidosubstituted arylboronic acids: Synthesis and Suzuki-Miyaura cross-coupling reactions
Sviridov, Sergey I.,Vasil'ev, Andrei A.,Sergovskaya, Natalia L.,Chirskaya, Marina V.,Shorshnev, Sergey V.
, p. 2639 - 2647 (2007/10/03)
Arylboronic acids having a remote azido group were prepared from the corresponding azidosubstituted aryl bromides via lithiation and treatment with trialkyl borates. Preparative yields were achieved when the starting aryl bromides possessed ortho-alkoxy groups, which would stabilize the intermediate aryllithium species. Conventional Suzuki cross-coupling of the arylboronic acids proceeded generally well with retention of azido group; however, sometimes azidomethyl fragment underwent oxidative transformation into a nitrile.
DIHYDROBENZOFURAN COMPOUNDS AND USES THEREOF
-
Page/Page column 34-35, (2010/02/15)
Dihydrobenzofuran compounds of Formula (I), including salts, prodrugs, hydrates and solvates thereof, that act as 5-HT2 receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in anima
FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS
-
Page/Page column 108, (2010/10/20)
Compounds of formula (I) wherein R1, R2, X, A, Y, B, Z1, Q, p, r and s are defined in the specification for treating inter alia psychotic disorders, depressive disorders, anxiety disorders and sexual dysfunctions.
